Diabetes & Metabolism Journal

Original Article

Complications
Global, Regional, and National Temporal Trends in Incidence for Type 2 Diabetes Mellitus Related Chronic Kidney Disease from 1992 to 2021: Yu Cao, Huiting Chen, Hui Liu, Hao Wu, Wei Gao; Diabetes Metab J. 2025;49(4):848-861. Published online March 11, 2025; DOI: https://doi.org/10.4093/dmj.2024.0593

10,260 View
244 Download
10 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Type 2 diabetes mellitus (T2DM) is a major cause of declining renal function.
Methods
Temporal trends in T2DM-related chronic kidney disease (CKD-T2DM) incidence across 204 countries and territories from 1992 to 2021 were analyzed using data from the Global Burden of Disease 2021. The impact of macro-factors (demographic change, age, period, and birth cohort) on CKD-T2DM incidence trends was assessed using decomposition analyses and age-period- cohort modeling, highlighting opportunities to improve incidence and reduce regional disparities.
Results
In 2021, global CKD-T2DM incidence cases reached 2.01 million, a 150.92% increase since 1992, with population growth and aging contributing to 80% of this rise. The age-standardized incidence rate (ASIR) ranged from 15.09 per 100,000 in low sociodemographic index (SDI) regions to 23.07 in high SDI regions. China, India, the United States, and Japan have the most incidence cases, accounted for 69% of incidence cases globally. With 175 countries showing an increasing ASIR trend. Unfavorable trend in ASIR increase were generally found in most high-middle and middle SDI countries, such as China and Mexico (net drift=0.15% and 1.17%, per year). Age-period-cohort analyses indicated a high incidence risk near age 80, with worsening risks for recent periods and birth cohorts, except in high SDI areas.
Conclusion
The CKD-T2DM incidence burden continues to rise globally, with significant variations between countries, posing major global health implications. CKD-T2DM is largely preventable and treatable, warranting greater attention in global health policy, particularly for older populations and in low and middle SDI regions.

Citations

Citations to this article as recorded by

Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
Jean-Michel Halimi, Laurent Fauchier, Alexandre Karras, Chloé Amouyal, Dominique Eladari, Patrick Rossignol, Gabriel Choukroun, Philippe Zaoui, Nicolas Girerd, Samy Hadjadj
European Journal of Preventive Cardiology.2026; 33(1): 8. CrossRef
Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis
Xiaojian Zhu, Xingjia Wang, Peiru Zhang, Zhuoshi Yang, Na Zhao, Jiameng Li, Yunze Shi, Yichen Zhao, Jian Ma
Frontiers in Endocrinology.2026;[Epub] CrossRef
2026 Latin American consensus for the management of patients with hypertension and cardio-renal and metabolic disturbances: endorsed by the Latin American Society of Hypertension, the Iberoamerican Hypertension League, and the World Hypertension League
Antonio Coca, Ramiro Sánchez, Dora I. Molina de Salazar, Ernesto Peñaherrera, Luis Alcocer, Eduardo Barbosa, Guido Grassi, Patricio Lopez-Jaramillo, Empar Lurbe, José Parra-Carrillo, Agustín J. Ramirez, Josep Redón, Weimar Sebba-Barroso, Andrés Acosta, Da
Journal of Hypertension.2026; 44(6): 885. CrossRef
Diabetic kidney disease: Radiological assessment and clinical correlations
Salvatore Silipigni, Guido Gembillo, Lorenzo Lo Cicero, Serena Ausilia Ferrara, Maria Federica Ricca, Giuseppe Spadaro, Luca Soraci, Antonio Bottari
World Journal of Diabetes.2026;[Epub] CrossRef
Global burden of chronic kidney disease due to type 2 diabetes in adults from 1990 to 2021, with exploratory projections to 2036: a systematic analysis of the Global Burden of Disease Study 2021
Yazhi Wang, Hui Chen
Diabetes Research and Clinical Practice.2026; 237: 113340. CrossRef
Burden and trends of chronic kidney disease due to type 2 diabetes mellitus in China and G20 countries, 1990–2023: a comparative analysis
Jincheng Li, Xinyu Li, Hongtao Zhao, Xinyu Yang, Yulin Li
Frontiers in Endocrinology.2026;[Epub] CrossRef
Prognostic value of the atherogenic index of plasma for early-stage diabetic kidney disease in type 2 diabetes: a retrospective cohort study using supervised machine learning
Yazhi Wang, Hui Chen
Frontiers in Nutrition.2026;[Epub] CrossRef
Silymarin attenuates diabetic nephropathy in rats via modulation of the miRNA-223/NLRP3/caspase-1/GSDMD axis and inflammasome-related pyroptotic signaling
Merna G. Aboismaiel, Mohamed N. Amin, Laila A. Eissa
Biology Direct.2026;[Epub] CrossRef
Frailty and incident diabetes among middle-aged and older adults: Evidence from a large prospective cohort in China
Yingzhen Gu, Xiaorong Han, Jinxing Liu, Yifan Li, Wei Zhang, Naqiang Lv, Aimin Dang
Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(10): 104114. CrossRef
Addressing Inequities in Early‐Onset Diabetic Kidney Failure in Australia: A Response to Ellis et al.
Gokhan Koker
Nephrology.2025;[Epub] CrossRef
An Overview of Sex-Based Differences in the Onset and Progression of DKD in the Well-Known Model, ZSF1 Rats
Arunita Chatterjee, Sharma S. Prabhakar
Life.2025; 15(10): 1627. CrossRef
Electroacupuncture ameliorates glycolipid metabolism disorder in skeletal muscle of type 2 diabetic rats via modulation of the AMPK/PGC-1α/TFAM signaling pathway
Fang Luo, Junjie Feng, Jumahan Nverjiang, Jiangnan Ye, Chang Liu, Hanhan Chen, Zhuoxuan Li, Qunwen Lu, Wei Zhang, Furong Zhang, Jun Zhu, Chengguo Su
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search